Sdi Share Discussion Threads

[rivaldo] 02/2/2017 11:49

Indeed. And more here:



"Friday 27th January 2017

Want to accelerate your workflow in the microbiology laboratory? Visit Synbiosis on stand number 140 at Arab Lab 0217 to find out how

Synbiosis, a long-established, expert manufacturer of automated microbiological systems, is proud to announce it will be showing its innovative range of time-saving equipment for microbiology applications on Stand 140 at ARABLAB 2017 on March 20th-23rd. The systems on display are guaranteed to improve productivity and accuracy of sample preparation and colony counting tasks.

For microbiologists needing to accurately generate 1 to 1/100 sample dilutions, Synbiosis is proudly displaying its ProDilute, next generation, precise gravimetric diluter. To blend samples the ProBlend, a quiet, safe, easy-clean blender, which is fully compatible with the ProDilute is going to be live on stand. Using this great diluter and blender combination, assures precise, rapid processing of food, environmental and clinical samples every time.

To further increase productivity, Synbiosis experts will be showing the Protos 3, developed for easy set-up and rapid colony counting. The other incredible capability of the Protos 3 is identifying microbial species by their colour on chromogenic plates and is one of the world’s only commercial colony counters to have this unique feature. The system provides accurate, objective, traceable GLP compliant results, making Protos 3 a great time saver and must-see product at ArabLab this year.

For dedicated colony counting, then aCOLyte 3 HD and aCOLade 2 are the systems to look at on the Synbiosis stand. Featuring high-resolution imaging and simple-to-use software, the aCOLyte 3 HD is an ideal choice for walk-away counting of colonies on pour and spiral plates. The aCOLade 2 manual colony counter with an illuminated pressure sensitive plate and large LED counting display is also on show and will suit any budget-conscious microbiologist....

.....“Busy microbiology labs often need great equipment to help increase throughput and improve their results.” comments Kate George, Senior Divisional Manager at Synbiosis, “We are delighted to be showcasing our latest product range on Stand 140 at ARABLAB this year, and we’re looking forward to explaining how their incredible performance will improve accuracy and increase productivity of microbial testing.”"

[hastings] 01/2/2017 12:58

Nice to hear of new products being showcased and in a growth area.

[rivaldo] 01/2/2017 12:16

News:



"Wednesday 25th January 2017

New generation Syngene gel doc systems for gel and blot imaging to be showcased on stand 140 at ArabLab 2017

Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to announce the new range of imaging systems will be on Stand 140 at ARABLAB 2017 on March 20th-23rd. Designed for simple set-up and accurate performance, there will be systems on display to suit all budgets and imaging applications.

Scientists looking for a low cost, yet powerful DNA and protein imaging system, should check out Syngene’s NuGenius, live on stand. This compact gel doc system, featuring a 5 million pixel CCD camera and motor driven zoom lens, enables perfect imaging of any gel or blot size up to 20cm x 24cm.

For those seeking dedicated chemiluminescence imagers, Syngene’s experts will be on hand to show the brilliantly designed GeneGnome XRQ imager. With an innovative low-light capture powerhouse of a camera and one-click set-up, generating superb images of barely-there chemiluminescent bands on Western blots has never been easier.

To complete Syngene’s range, the PXi all-round multi-functional imaging system is available for scientists to try. This system, complete with high resolution, cooled camera and innovative touch-screen GeneSys image capture software can handle anything with ease, from chemiluminescent and fluorescent blots, visible gels and blots, right through to more complex 2D gels.

Scientists wanting to find out more about any of these exciting imagers, should click these links for details: hxxp://www.syngene.com/nugenius-gel-imaging-system/ hxxp://www.syngene.com/genegnome-xrq/ hxxp://www.syngene.com/pxi-pxi-touch/

“ARABLAB is always such a great show and we’re excited to be exhibiting our latest range of intelligently designed gel doc systems here.” comments Matthew Dunne, Senior Divisional Manager at Syngene. “We look forward to welcoming scientists on Stand 140 and to letting them see how imaging technology produced in one of the world’s most renowned innovation hubs, could significantly benefit their research.”

[cockerhoop] 27/1/2017 15:37

Apols Rivaldo, Hastings! I guess the £1.1m this year is pre the deferred consideration of approx £1.3m if Astles hit their profit target.

[cockerhoop] 27/1/2017 14:36

They no longer have a cash pile Rivaldo, they spent it on Astles (not that that wasn't a decent way to spend the money!)

[rivaldo] 27/1/2017 11:54

Great article hastings, many thanks. You've laid out all the fundamentals and the potential.

On a P/E of 9.9 - and much less if you strip out the cash pile - with new product potential and acquisitions in the pipeline, what more do people need?

Let's see if this direct link works better:

[noble3r] 25/1/2017 14:25

surely its been tested by now...

hxxp://www.idsc-uk.co.uk/docs2015/MRRS_4101_Synoptics_ProReveal.pdf

[pj 1] 25/1/2017 10:40

Very apt and well written as always Hastings. I wish I ad thet skil. :-//

[noble3r] 25/1/2017 10:36

great article - thanks for sharing the link.

I never had FinnCap's forecasts for 17/18, are their reports in the public domain?

Enjoyed reading:

'...Astles, which is currently enjoying its busiest month'
'...revamping the original Syngene aspect of the business'
'...the company already has its eye on a number of potential candidates'


GLA

[hastings] 25/1/2017 10:02

Penned a piece yesterday which may be of interest to others after dropping in on SDI.Whilst the lack of comment on ProReveal may imply nothing is happening, I suspect that it is more a case of the CEO preferring to await for something meaningful to report.Http://www.cambridge-news.co.uk/business/technology/cambridge-company-watch-sdi-unveils-12503285

[luckymouse] 24/1/2017 14:22

500k pbt finals - then 400k pbt ints - looks fierce - but ceo avoided using the 'ahead' word? Up 100% since finals so main trading bang already happened perhaps. Prob worth 25-30p fwd - so a 15p dip could be nice play.

[noble3r] 24/1/2017 13:30

this is an extremely illiquid stock. I realise it cannot easily be sold. In time an orderly market will come but we are still at the very early stages of this companies journey.

[basem1] 24/1/2017 13:08

Just try selling at 18p though.

[basem1] 24/1/2017 13:07

18p to buy with iii.

[noble3r] 24/1/2017 13:04

some very strange ASK & BID price movement this afternoon. I couldn't resist at 18p.

[basem1] 24/1/2017 10:00

No, you'd use the entire share capital figure. I assume 89m is correct.

[noble3r] 24/1/2017 09:57

should we not be using the 23,769,231 placing shares as our figure to calulate Astles EPS?

[basem1] 24/1/2017 09:50

I remember seeing a previous post calculating 1.7 or 2.2 with Astles. But Circa £500k divided by 89m shares in issue = 0.56p Approximate profit figure. I stand to be corrected.

[noble3r] 24/1/2017 09:44

@basem1: how have you calculated Astles EPS?

[shanklin] 24/1/2017 09:41

With this document in the public domain, any hospital which causes a patient serious health problems by not implementing its instrument cleaning requirements, whatever the deadlines identified by the DoH, is presumably going to legally be in a very weak position.

[netcurtains] 24/1/2017 09:17

this share was on Mudbaths thread: "Shares to double by end of 2017"....
So, if that post was right, could be 40p by Christmas

[hastings] 24/1/2017 09:11

PJ1,I largely agree with you on the point of ProReveal and expectations, which is most likely in part due to the share price spike up to the dizzy heights of 28p back in 2013.
My understanding is that previous management of the system believed the NHS would quickly embrace the tech, and why not.

Mike Creedon is very much a realist and is not in the business of overplaying prospects, being fully aware of the slow and grinding mechanics of the NHS.

That said, if there is something meaningful to report on ProReveal they will no doubt update us as and when.

I take heart from the Chairman's comments below and from my last visit when speaking to one of the team on the system.
Hopefully, this will now on the back of the guidance as posted by Shanklin above really be a matter of timing, which is moving increasingly closer.

"The uptake of the test has been slower by the NHS in the UK. However, since the UK Department of Health (DoH) published additional new guidelines in July 2016 which provide the limit of acceptable protein contamination on re-usable surgical instruments ( there has been increased interest in ProReveal. Currently, it is the only available CE-marked instrument capable of measuring less than 50ng of protein and thus meeting DoH requirements".

[noble3r] 24/1/2017 09:11

cash on the balance sheet post Astles acquisition approx £350k.
£498k cash generated from operations for last 6 months so I'd expect cash on balance sheet back to £1mill come full yr results

[shanklin] 24/1/2017 08:57

Re the NHS as mentioned above... ...from the report



referenced in the RNS, on page 6 of 59 it states:

"This guidance provides information on how sterile services departments (SSDs) can mitigate the patient safety risk from residual protein with a move towards first achieving this ≤5 μg level and subsequently producing further reductions in protein contamination levels through the optimisation of decontamination processes. The ambition is that all healthcare providers engaged in the management and decontamination of surgical instruments used in acute care will be expected to
have implemented this guidance by 1 July 2018. However, providers whose instruments are likely to come into contact with higher risk tissues, for example neurological tissue, are expected to give this guidance higher priority and move to in situ protein detection methodologies by 1 July 2017."

So, until then, the NHS presumably views it as perfectly acceptable to put patients at unnecessary risk.

HTH.